Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + TAS-102 for third-line advanced colorectal cancer
ChiCTR2300078241Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fruquintinib and trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Objective response rate. Started Aug 2023; status: recruiting.
02
Drugs
fruquintinibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300078241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078241.